NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $84,000 | -92.2% | 15,596 | -80.5% | 0.01% | -87.5% |
| Q4 2021 | $1,082,000 | +177.4% | 80,101 | +269.2% | 0.04% | +100.0% |
| Q3 2021 | $390,000 | -81.4% | 21,696 | -82.2% | 0.02% | -77.8% |
| Q2 2021 | $2,095,000 | +810.9% | 122,111 | +960.6% | 0.09% | +592.3% |
| Q1 2021 | $230,000 | +10.6% | 11,513 | -6.1% | 0.01% | -23.5% |
| Q4 2020 | $208,000 | -34.2% | 12,262 | -35.5% | 0.02% | -50.0% |
| Q3 2020 | $316,000 | +17.9% | 19,020 | +29.4% | 0.03% | +112.5% |
| Q3 2019 | $268,000 | – | 14,696 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |